ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Investigating the amyloid-tau-neurodegeneration framework in Alzheimer's disease using semi-supervised multimodal imaging data fusion.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating the amyloid-tau-neurodegeneration framework in Alzheimer's disease using semi-supervised multimodal imaging data fusion.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
introductionAlzheimer's disease (AD) heterogeneity complicates diagnosis and prognosis. Uncovering amyloid-tau-neurodegeneration (A-T-N) patterns may improve diagnostic prediction.
methodsWe applied SuperBigFLICA (SBF), a semi-supervised multimodal fusion method, to gray matter density, cortical thickness (CT), pial surface area, amyloid and tau positron emission tomography maps from 274 Alzheimer's Disease Neuroimaging Initiative 3 participants to derive 50 latent components predictive of cognitive decline. Subject loadings were then used to predict diagnosis (cognitively normal, mild cognitive impairment, dementia) and apolipoprotein E (
resultsSBF modestly predicted out-of-sample concurrent clinical severity (Clinical Dementia Rating Sum of Boxes; DISCUSSION: SBF improves prediction and reveals interpretable patterns that better classify clinical diagnoses and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.